WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY) reintroduced the Federal Reserve Transparency Act or the “Audit the Fed” bill, to prevent the Federal Reserve from concealing vital information on its operations from Congress.
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, released his 2023 “Festivus” Report, totaling ~$900,000,000,000 in government waste.
WASHINGTON, D.C. – Yesterday, as a continuation of his efforts to protect individual freedoms and put an end to unscientific mandates, U.S. Senator Rand Paul (R-KY) introduced a resolution that would have protected Senate Pages from the imposition of COVID-19 vaccination requirements.
WASHINGTON, D.C. – Today, in a continuation of his efforts to protect Americans’ civil liberties and push for reform to Section 702 of the Foreign Intelligence Surveillance Act (FISA), U.S. Senator Rand Paul (R-KY) forced a Senate vote to remove reauthorization of FISA from the annual National Defense Authorization Act (NDAA).
WASHINGTON, D.C. – Today, U.S. Senators Rand Paul (R-KY), Joe Manchin (D-WV), and Ted Budd (R-NC) sent a letter to Dr. Robert Califf, Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) urging the FDA Center for Tobacco Products (CTP) to reform its application review process for harm-reduced products. The Senators also requested information about CTP’s policies and actions to ensure it is acting efficiently and in a way that is based on science and evidence.
WASHINGTON, D.C. – Today, U.S. Senators Rand Paul (R-KY) and Edward J. Markey (D-MA), chair of the Health, Education, Labor and Pensions (HELP) Subcommittee on Primary Health and Retirement Security, issued the following statement after the Senate HELP Committee passed the Modernizing Opioid Treatment Access Act (MOTAA), legislation to allow board certified addiction medicine and addiction psychiatry doctors registered with the Drug Enforcement Administration (DEA) to prescribe methadone that patients could pick up at a pharmacy. The bipartisan legislation would represent the first major reform to methadone in half a century and is supported by hundreds of clinicians and medical organizations.
WASHINGTON, D.C. – Yesterday, as a continuation of his efforts to return war powers to Congress and end the American military presence in Syria, which needlessly puts our troops’ lives in danger and risks further escalation of conflict in the Middle East, U.S. Senator Rand Paul (R-KY) forced the U.S. Senate to vote on his War Powers Resolution (S.J. Res. 51). His resolution directed the president to remove all U.S. Armed Forces from hostilities in and affecting Syria within 30 days of its enactment. Dr. Paul’s resolution was co-sponsored by U.S. Senators Mike Lee (R-UT) and JD Vance (R-OH).
WASHINGTON, D.C. – Today, as a continuation of his efforts to return war powers to Congress and end the American military presence in Syria, which needlessly puts our troops’ lives in danger and risks further escalation of conflict in the Middle East, U.S. Senator Rand Paul (R-KY) will force the U.S. Senate to vote on his War Powers Resolution (S.J. Res. 51). His resolution directs the president to remove all U.S. Armed Forces from hostilities in and affecting Syria within 30 days of its enactment. Dr. Paul’s resolution is currently co-sponsored by U.S. Senators Mike Lee (R-UT) and JD Vance (R-OH).
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY) and Senate Republican Leader Mitch McConnell (R-KY) wrote a letter to the Biden Administration urging quick action to protect the millions of U.S. jobs that rely on American bourbon and spirits producers. Without urgent action, the European Union (EU) will implement a 50% tariff on American whiskey imports on January 1, 2024, and American wine and other distilled spirits imports could see sharp tariff increases by 2026.
WASHINGTON, D.C. – Yesterday, U.S. Senator Rand Paul (R-KY) sent a letter to Dr. Robert Califf, Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) about the FDA’s recent proposed rule on Laboratory Developed Tests (LDTs). The proposed rule would inappropriately impose the FDA’s medical device regulatory framework on health care providers developing and performing LDTs as part of their professional practice. It would also cause unnecessary disruptions to patient care.